MedTrace Logo

A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivitis

NCT07169695 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-04-22

No results posted yet for this study

Summary

The aim of the study is to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants with Moderate to Severe Vernal Keratoconjunctivitis

Conditions

  • Moderate to Severe Vernal Keratoconjunctivitis

Interventions

DIAGNOSTIC_TEST

Slit Lamp Examination

The participant will have a slit lamp examination

DIAGNOSTIC_TEST

Far Best Corrected Visual Acuity (BCVA)

The participant 's BCVA will be evaluated.

DRUG

T1695

The participant should instill T1695.

DRUG

Ciclosporin

The participant should instill Ciclosporin.

DIAGNOSTIC_TEST

Corneal fluorescein staining score on modified Oxford scale

One drop of fluorescein will be instilled to assess the fluorescein staining score on the modified Oxford scale.

Sponsors & Collaborators

  • Laboratoires Thea

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
4 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-24
Primary Completion
2027-01-21
Completion
2027-01-21

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07169695 on ClinicalTrials.gov